Nina Sharma
Family · Sparks, MDNPI 1205419777
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.2% of the total across 1,143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 8.6% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,143 payments — averaging $22.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novartis$2K
- AstraZeneca$2K
- EMD Serono, Inc.$1K
- Livanova USA, Inc.$1K
- Biogen$1K
- plus $16K from 54 others
What the payments were for
- Consulting fees$9904%
- Travel & lodging$7313%
- Food & beverage$24,11292%
- Education$3051%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,245
- ULTOMIRIS$1,132
- ZEPOSIA$735
- NIDRA$164
- TYSABRI$107
How this compares
$26,138 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuedextaDextromethorphan Hbr/Quinidine | 30 | $49,245 |
| UbrelvyUbrogepant | 12 | $32,462 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 16 | $26,339 |
| Emgality PenGalcanezumab-Gnlm | 14 | $16,160 |
| Dalfampridine ErDalfampridine | 16 | $10,654 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $10,088 |
| Lacosamide | 17 | $3,616 |
| Divalproex Sodium | 64 | $1,767 |
| Gabapentin | 66 | $1,388 |
| Duloxetine Hcl | 44 | $1,341 |
| Pregabalin | 27 | $1,209 |
| Primidone | 27 | $1,099 |
| Levetiracetam | 33 | $867 |
| Donepezil Hcl | 61 | $645 |
| Carbamazepine | 13 | $422 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Avanir Pharmaceuticals, Inc.Nuedexta | $61 | $49,24530 claims |
| AbbVieUbrelvy | $2,248 | $32,46212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.
Other family in Sparks
- Erika HoffmanPotomac$226K
- Caroline MansySalisbury$106K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Ariana ChaoLutherville$85K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
- Joy MaulikSalisbury$47K
- Kristin AttiogbeChevy Chase$42K
- Sametta SanyaoluFulton$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.